Published in J Clin Invest on February 01, 1993
Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med (1994) 2.37
HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet (2003) 2.02
Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol (1997) 1.98
Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J Exp Med (1998) 1.94
Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J Exp Med (1994) 1.81
Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics (2011) 1.68
Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes. J Virol (2001) 1.62
Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol (2000) 1.52
Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. J Exp Med (1995) 1.37
Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity. Proc Natl Acad Sci U S A (1994) 1.37
Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med (1999) 1.33
Five HLA-DP molecules frequently expressed in the worldwide human population share a common HLA supertypic binding specificity. J Immunol (2010) 1.29
Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. J Clin Invest (1993) 1.27
The T cell response of HLA-DR transgenic mice to human myelin basic protein and other antigens in the presence and absence of human CD4. J Exp Med (1995) 1.23
Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes. J Clin Invest (1997) 1.21
Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection. EMBO J (2011) 1.17
Deimination of membrane-bound myelin basic protein in multiple sclerosis exposes an immunodominant epitope. Proc Natl Acad Sci U S A (2006) 1.11
Expression and crystallization of the complex of HLA-DR2 (DRA, DRB1*1501) and an immunodominant peptide of human myelin basic protein. Proc Natl Acad Sci U S A (1998) 1.09
Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B-cell epitope and a model of its features. Proc Natl Acad Sci U S A (1995) 1.07
Naturally presented peptides on major histocompatibility complex I and II molecules eluted from central nervous system of multiple sclerosis patients. Mol Cell Proteomics (2009) 1.01
The immunopathophysiology of multiple sclerosis. Neurol Clin (2011) 0.99
Complementary mutations in an antigenic peptide allow for crossreactivity of autoreactive T-cell clones. Proc Natl Acad Sci U S A (1996) 0.98
Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein. J Clin Invest (1996) 0.98
Unusual features of self-peptide/MHC binding by autoimmune T cell receptors. Immunity (2005) 0.97
Structure of human T-cell receptors specific for an immunodominant myelin basic protein peptide: positioning of T-cell receptors on HLA-DR2/peptide complexes. Proc Natl Acad Sci U S A (1995) 0.95
Promiscuous presentation and recognition of nucleosomal autoepitopes in lupus: role of autoimmune T cell receptor alpha chain. J Exp Med (1998) 0.93
Do MHCII-presented neoantigens drive type 1 diabetes and other autoimmune diseases? Cold Spring Harb Perspect Med (2012) 0.92
Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action. Biologics (2013) 0.92
Myelin-reactive type B T cells and T cells specific for low-affinity MHC-binding myelin peptides escape tolerance in HLA-DR transgenic mice. J Immunol (2008) 0.92
DQB1*0602 rather than DRB1*1501 confers susceptibility to multiple sclerosis-like disease induced by proteolipid protein (PLP). J Neuroinflammation (2012) 0.91
Associations of human leukocyte antigens with autoimmune diseases: challenges in identifying the mechanism. J Hum Genet (2015) 0.91
Cell-surface MHC density profiling reveals instability of autoimmunity-associated HLA. J Clin Invest (2014) 0.90
Human self-reactive T cell clones expressing identical T cell receptor beta chains differ in their ability to recognize a cryptic self-epitope. J Exp Med (1996) 0.88
Mycobacterial ESAT-6 and katG are recognized by sarcoidosis CD4+ T cells when presented by the American sarcoidosis susceptibility allele, DRB1*1101. J Clin Immunol (2009) 0.87
Immunopathogenesis of multiple sclerosis: MBP and beyond. Clin Exp Immunol (2002) 0.85
Diversity and dynamics of the T-cell response to MBP in DR2+ve individuals. Clin Exp Immunol (2002) 0.83
Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases. Front Immunol (2015) 0.83
Adduction of cholesterol 5,6-secosterol aldehyde to membrane-bound myelin basic protein exposes an immunodominant epitope. Biochemistry (2011) 0.82
The fine specificity of human T cell lines towards myelin basic protein peptides in southern Italian multiple sclerosis patients. Clin Exp Immunol (2001) 0.79
Conformational analysis of the ΜΒΡ83-99 (Phe91) and ΜΒΡ83-99 (Tyr91) peptide analogues and study of their interactions with the HLA-DR2 and human TCR receptors by using molecular dynamics. J Comput Aided Mol Des (2011) 0.78
Myelin basic protein-specific TCR/HLA-DRB5*01:01 transgenic mice support the etiologic role of DRB5*01:01 in multiple sclerosis. J Immunol (2012) 0.78
Small molecule inhibitor of antigen binding and presentation by HLA-DR2b as a therapeutic strategy for the treatment of multiple sclerosis. J Immunol (2013) 0.77
A molecular view of multiple sclerosis and experimental autoimmune encephalitis: what can we learn from the epitope data? J Neuroimmunol (2013) 0.76
Expanding Role of T Cells in Human Autoimmune Diseases of the Central Nervous System. Front Immunol (2017) 0.75
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (1983) 40.64
PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS. Ann N Y Acad Sci (1965) 6.34
T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature (1990) 4.40
Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol (1989) 4.29
T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature (1987) 3.96
The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol (1981) 3.96
T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature (1985) 3.71
MHC class-II molecules and autoimmunity. Annu Rev Immunol (1991) 3.41
A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature (1989) 3.33
Limited heterogeneity of rearranged T-cell receptor V alpha transcripts in brains of multiple sclerosis patients. Nature (1990) 3.30
Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes. J Immunol (1981) 3.15
Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein. Science (1990) 2.86
T cells responsive to myelin basic protein in patients with multiple sclerosis. Science (1990) 2.77
Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J Immunol (1989) 2.70
Detection of a novel human class II HLA antigen. Nature (1983) 2.61
A population-based study of multiple sclerosis in twins. N Engl J Med (1986) 2.59
A molecular model of MHC class-I-restricted antigen processing. Immunol Today (1992) 2.55
On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs. J Immunol (1991) 2.49
Human Ia molecules carrying DC1 determinants differ in both alpha- and beta-subunits from Ia molecules carrying DR determinants. Nature (1981) 2.39
Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line. J Biol Chem (1987) 2.27
Autoimmune diseases: the failure of self tolerance. Science (1990) 2.24
Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol (1990) 2.07
How some T cells escape tolerance induction. Nature (1989) 2.03
T-cell recognition of myelin basic protein. Immunol Today (1991) 1.98
Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci U S A (1990) 1.93
Mechanisms influencing the immunodominance of T cell determinants. J Exp Med (1988) 1.91
Distinct forms of both alpha and beta subunits are present in the human Ia molecular pool. Proc Natl Acad Sci U S A (1981) 1.91
A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis. J Exp Med (1991) 1.84
Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition. J Immunol (1991) 1.75
Preferential T-cell receptor beta-chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis. Proc Natl Acad Sci U S A (1991) 1.47
Effect of pH on MHC class II-peptide interactions. J Immunol (1992) 1.46
T-cell receptor alpha chain germline gene polymorphisms in multiple sclerosis. Neurology (1992) 1.43
Characterization of the specificity of peptide binding to four DR haplotypes. J Immunol (1990) 1.43
Diversity in fine specificity and T cell receptor usage of the human CD4+ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. J Immunol (1992) 1.40
Restricted T-cell receptor V beta gene usage by myelin basic protein-specific T-cell clones in multiple sclerosis: predominant genes vary in individuals. Proc Natl Acad Sci U S A (1991) 1.31
Multiple sclerosis: gadolinium enhancement in MR imaging. Radiology (1986) 1.29
T cell receptors in murine autoimmune diseases. Annu Rev Immunol (1989) 1.26
Truncation analysis of several DR binding epitopes. J Immunol (1991) 1.24
Experimental allergic encephalomyelitis in the rat: response to encephalitogenic proteins and peptides. Science (1973) 1.21
Molecular mimicry as a mechanism for the cause and a probe uncovering etiologic agent(s) of autoimmune disease. Curr Top Microbiol Immunol (1989) 1.21
Sardinian multiple sclerosis is associated with HLA-DR4: a serologic and molecular analysis. Neurology (1988) 1.17
Response of human T lymphocyte lines to myelin basic protein: association of dominant epitopes with HLA class II restriction molecules. J Neurosci Res (1989) 1.16
High affinity for class II molecules as a necessary but not sufficient characteristic of encephalitogenic determinants. Int Immunol (1992) 1.10
T cell response to myelin basic protein epitopes in multiple sclerosis patients and healthy subjects. Eur J Immunol (1991) 1.06
Immunochemically purified DR antigens in liposomes stimulate xenogeneic cytolytic T cells in secondary in vitro cultures. Cell Immunol (1986) 1.02
Nomenclature for factors of the HLA system, 1990. Hum Immunol (1991) 1.01
A novel approach to the generation of high affinity class II-binding peptides. J Immunol (1990) 1.00
Lessons from magnetic resonance imaging in multiple sclerosis. Trends Neurosci (1989) 0.99
Diversity of T cell receptor alpha and beta chain genes expressed by human T cells specific for similar myelin basic protein peptide/major histocompatibility complexes. Eur J Immunol (1992) 0.97
HLA and Japanese MS. Tissue Antigens (1978) 0.94
Multiple sclerosis in Saudi Arabia. Neurology (1988) 0.94
HLA-DR2a is the dominant restriction molecule for the cytotoxic T cell response to myelin basic protein in DR2Dw2 individuals. J Immunol (1990) 0.94
Multiple sclerosis and HLA: is the susceptibility gene really HLA-DR or -DQ? Hum Immunol (1991) 0.93
Peptides of myelin basic protein stimulate T lymphocytes from patients with multiple sclerosis. J Neuroimmunol (1989) 0.90
Immunogenetic profile of multiple sclerosis in Mexicans. Hum Immunol (1986) 0.87
Peptide specificities of myelin basic protein-reactive human T-cell clones. Neurology (1988) 0.83
Non-radioactive oligotyping for HLA-DR1-DRw10 using polymerase chain reaction, digoxigenin-labelled oligonucleotides and chemiluminescence detection. Eur J Immunogenet (1992) 0.81
Influence of HLA-DR2, HLA-DPw4, and T cell receptor alpha chain genes on the susceptibility to multiple sclerosis. Int Immunol (1992) 0.77
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature (2000) 9.80
The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol (1998) 5.50
The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science (1987) 5.32
Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med (1999) 4.93
Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics (1999) 4.88
Isolation and characterization of antigen-Ia complexes involved in T cell recognition. Cell (1986) 4.71
Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature (1994) 4.42
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol (1994) 4.37
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
The minimal number of class II MHC-antigen complexes needed for T cell activation. Science (1990) 4.09
Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med (1997) 4.04
Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol (1998) 3.95
1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol (2000) 3.82
Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell (1993) 3.80
Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J Immunol (1998) 3.65
Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature (1987) 3.63
The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity (2001) 3.52
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol (1996) 3.45
Differential effects of cytolytic T cell subsets on intracellular infection. Science (1997) 3.39
Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science (1992) 3.39
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J Exp Med (1998) 3.35
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med (1995) 3.34
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell (1992) 3.24
Nomenclature for factors of the HLA system, 2010. Tissue Antigens (2010) 3.22
Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest (1997) 2.99
Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity (1994) 2.90
Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med (1995) 2.80
Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol (2001) 2.75
Immunological self, nonself discrimination. Science (1987) 2.59
Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol (1997) 2.57
On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs. J Immunol (1991) 2.49
Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med (1994) 2.37
Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol (1995) 2.34
MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology (2010) 2.33
Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice. Virology (1998) 2.31
Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol (2000) 2.29
Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J Exp Med (1995) 2.29
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology (2011) 2.26
The interaction between protein-derived immunogenic peptides and Ia. Immunol Rev (1987) 2.24
Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. J Immunol (1996) 2.24
Why peptides? Their possible role in the evolution of MHC-restricted T-cell recognition. Immunol Today (1989) 2.23
Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med (1994) 2.18
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med (1996) 2.17
Conserved T cell receptor repertoire in primary and memory CD8 T cell responses to an acute viral infection. J Exp Med (1998) 2.13
Fine specificity of regulatory T cells. II. Suppressor and helper T cells are induced by different regions of hen egg-white lysozyme in a genetically nonresponder mouse strain. J Exp Med (1979) 2.12
Definition of specific peptide motifs for four major HLA-A alleles. J Immunol (1994) 2.11
Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways. Nature (1990) 2.11
Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med (2001) 2.10
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology (2008) 2.07
Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol (1994) 2.07
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry (1991) 2.05
Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol (1995) 2.05
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology (2010) 2.04
Nomenclature for factors of the HLA system, 1990. Tissue Antigens (1991) 1.98
Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol (1997) 1.98
Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci U S A (1990) 1.93
Self glycolipids as T-cell autoantigens. Eur J Immunol (1999) 1.93
Autologous peptides constitutively occupy the antigen binding site on Ia. Science (1988) 1.92
Different functional specificity repertoires for suppressor and helper T cells. Immunol Rev (1978) 1.91
MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90
Nomenclature for factors of the HLA system, 2002. Tissue Antigens (2002) 1.89
Analysis of HL-A incompatibility in human renal transplants. Tissue Antigens (1971) 1.89
A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology (2002) 1.86
Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity (1997) 1.84
Human memory CTL response specific for influenza A virus is broad and multispecific. Hum Immunol (2000) 1.84
Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology (2011) 1.83
Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity (1995) 1.83
HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles. J Immunol (2000) 1.82
Cutting edge: selective usage of chemokine receptors by plasmacytoid dendritic cells. J Immunol (2001) 1.82
Cardiomyocytes induce endothelial cells to trans-differentiate into cardiac muscle: implications for myocardium regeneration. Proc Natl Acad Sci U S A (2001) 1.81
Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol Immunol (1994) 1.80
Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today (1996) 1.79